Dataset Information
Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial.
Ontology highlight
ABSTRACT:
SUBMITTER: Modjarrad K
PROVIDER: S-EPMC7185789 | biostudies-literature | 2019 Sep
REPOSITORIES: biostudies-literature
Publications
Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial.
The Lancet. Infectious diseases 20190724 9
<h4>Background</h4>Middle East respiratory syndrome (MERS) coronavirus causes a highly fatal lower-respiratory tract infection. There are as yet no licensed MERS vaccines or therapeutics. This study (WRAIR-2274) assessed the safety, tolerability, and immunogenicity of the GLS-5300 MERS coronavirus DNA vaccine in healthy adults.<h4>Methods</h4>This study was a phase 1, open-label, single-arm, dose-escalation study of GLS-5300 done at the Walter Reed Army Institute for Research Clinical Trials Cen ...[more]
